Rongrong Zheng

Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).

Chengping Hu, Gang Wu, Yong Fang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma

Zhenggang Zhu, M. Yan, Chen Li, 2020, Annals of translational medicine.

The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction

Yuan Ji, Jiping Wang, Qian Li, 2022, Nature Communications.

Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.

Pengfei Ma, Chengjuan Zhang, Yuzhou Zhao, 2024, Clinical and translational medicine.

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Z. Hou, Rongrong Zheng, Xian-kai Chen, 2024, Nature medicine.